FDA approves first-of-its-kind nasal spray for severe depression
4 days ago · Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...
FDA Approves Nasal Spray for Depression - Newsweek
3 days ago · This new treatment could help bring relief for millions of Americans struggling with depression. What To Know. The nasal spray Spravato, which is made from the drug esketamine, had been approved ...
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
2 days ago · A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.. The FDA first approved the Johnson & Johnson drug, called Spravato (esketamine), for some cases of depression in 2019, but it was only allowed to be prescribed alongside an oral antidepressant.
SPRAVATO® (esketamine): A Prescription Nasal Spray
SPRAVATO®, the only FDA-approved nasal spray for adults with treatment-resistant depression, reduces depression symptoms when two or more oral antidepressants haven't worked. SPRAVATO® can be taken with or without an oral antidepressant.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
2 days ago · The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.. Spravato is the first and only approved monotherapy for …
FDA allows standalone use of nasal spray antidepressant Spravato ...
4 days ago · The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression.
Ketamine-Derived Nasal Spray Approved as Standalone …
3 days ago · An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato ...
FDA OKs Esketamine Nasal Spray Monotherapy for Depression
1 day ago · The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded to at least two oral antidepressants. This site is intended for ...
FDA approves new nasal spray medication for treatment-resistant ...
The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried...
Esketamine for Treatment-Resistant Depression - Johns Hopkins Medicine
Esketamine is made from a drug called ketamine, an anesthetic that has also been used for many years to treat depression. But it wasn’t until recently that esketamine, a more potent version of ketamine, earned FDA approval specifically for use as a nasal spray for those with treatment-resistant depression.